ScholarIQanswers from OpenAlex & ORCID
Véronique Dièras
ResearcherPublications, citations & collaboration network
Véronique Dièras is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Véronique Dièras have?
ScholarIQindexed works
Véronique Dièras has 622 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Véronique Dièras have?
ScholarIQcitation count
Véronique Dièras has 44,361 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Véronique Dièras?
ScholarIQh-index
Véronique Dièras has an h-index of 85 in OpenAlex.
What is the i10-index of Véronique Dièras?
ScholarIQi10-index
Véronique Dièras has an i10-index of 261 in OpenAlex.
What is the ORCID of Véronique Dièras?
ScholarIQorcid
The ORCID for Véronique Dièras is on the source record.
What is the OpenAlex record for Véronique Dièras?
ScholarIQopenalex
The OpenAlex for Véronique Dièras is on the source record.
What are the most-cited papers on Véronique Dièras?
ScholarIQmost cited works
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus, Matti Aapro, Fabrice André, Carlos H. Barrios, Jonas Bergh, G.S. Bhattacharyya, Laura Biganzoli, Maria João Cardoso, L. Carey, D. Corneliussen-James, Giuseppe Curigliano, Véronique Dièras, N. El Saghir, Alexandru Eniu, Lesley Fallowfield, D. Fenech, Prudence A. Francis, Karen A. Gelmon, Alessandra Gennari, Nadia Harbeck, Clifford A. Hudis, Bella Kaufman, Ian E. Krop, Musa Mayer, Hanneke Meijer, Shirley Mertz, Shinji Ohno, Olivia Pagani, Efthymios Papadopoulos, Fedro A. Peccatori, Frédérique Penault‐Llorca, Martine Piccart, Jean‐Yves Pierga, Hope S. Rugo, Lillie D. Shockney, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Andrew Tutt, Daniel Vorobiof, Binghe Xu, Larry Norton, Eric P. Winer
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Fátima Cardoso, Elżbieta Senkus, A. Costa, Efthymios Papadopoulos, Matti Aapro, Fabrice André, Nadia Harbeck, B. Aguilar Lopez, C.H. Barrios, Jonas Bergh, Laura Biganzoli, C.B. Boers-Doets, Maria João Cardoso, L.A. Carey, Javier Cortés, Giuseppe Curigliano, Véronique Dièras, Nagi S. El Saghir, Alexandru Eniu, Lesley Fallowfield, P.A. Francis, Karen A. Gelmon, S. Johnston, Bella Kaufman, Smruti Koppikar, I.E. Krop, Musa Mayer, Gertrude Nakigudde, B.V. Offersen, Shinji Ohno, Olivia Pagani, Shani Paluch–Shimon, Frédérique Penault‐Llorca, Aleix Prat, H.S. Rugo, G. W. Sledge, Danielle Spence, Christoph Thomssen, D.A. Vorobiof, B. Xu, Larry Norton, E.P. Winer
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert, Véronique Dièras, John A. Glaspy, Adam Brufsky, Igor Bondarenko, Oleg Lipatov, Edith A. Perez, Denise A. Yardley, Stephen Chan, Xian Zhou, S. Phan, Joyce O’Shaughnessy
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortés, Véronique Dièras, Debra A. Patt, Hans Wildiers, Clifford A. Hudis, Joyce O’Shaughnessy, Esther Zamora, Denise A. Yardley, Martin Frenzel, Andrew Koustenis, José Baselga